A network meta-analysis of first-line treatment options for patients with Child-Pugh class B functional hepatocellular carcinoma: comparison of efficacy and safety.

Front Pharmacol · 2025 · PMC12807933 · PMID 41552825

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Although nivolumab showed a numerical trend towards improved OS, this difference warrants cautious interpretation.

also in 669 other papers

showed a trendno p-value reported

Additionally, although the difference was not statistically significant, nivolumab showed a trend towards lower discontinuation rates compared to sorafenib due to toxicity or clinical deterioration.

also in 26,766 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.